BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 25610780)

  • 1. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
    Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
    Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
    Morbelli S; Bauckneht M; Arnaldi D; Picco A; Pardini M; Brugnolo A; Buschiazzo A; Pagani M; Girtler N; Nieri A; Chincarini A; De Carli F; Sambuceti G; Nobili F
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2073-2083. PubMed ID: 28785843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting.
    Perani D; Della Rosa PA; Cerami C; Gallivanone F; Fallanca F; Vanoli EG; Panzacchi A; Nobili F; Pappatà S; Marcone A; Garibotto V; Castiglioni I; Magnani G; Cappa SF; Gianolli L;
    Neuroimage Clin; 2014; 6():445-54. PubMed ID: 25389519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia.
    Della Rosa PA; Cerami C; Gallivanone F; Prestia A; Caroli A; Castiglioni I; Gilardi MC; Frisoni G; Friston K; Ashburner J; Perani D;
    Neuroinformatics; 2014 Oct; 12(4):575-93. PubMed ID: 24952892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
    Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
    Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of FDG-PET for the clinical diagnosis in MCI.
    Arbizu J; Festari C; Altomare D; Walker Z; Bouwman F; Rivolta J; Orini S; Barthel H; Agosta F; Drzezga A; Nestor P; Boccardi M; Frisoni GB; Nobili F;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1497-1508. PubMed ID: 29704037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain fluorodeoxyglucose (FDG) PET in dementia.
    Kato T; Inui Y; Nakamura A; Ito K
    Ageing Res Rev; 2016 Sep; 30():73-84. PubMed ID: 26876244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementarity of visual and voxel-based FDG-PET analysis to detect MCI-like hypometabolic pattern in elderly patients with hypertension and isolated memory complaints.
    Van Der Gucht A; Verger A; Yagdigul Y; Poussier S; Joly L; Watfa G; Benetos A; Karcher G; Marie PY
    Acta Radiol; 2015 Aug; 56(8):980-9. PubMed ID: 25085109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.
    Mosconi L; Tsui WH; Herholz K; Pupi A; Drzezga A; Lucignani G; Reiman EM; Holthoff V; Kalbe E; Sorbi S; Diehl-Schmid J; Perneczky R; Clerici F; Caselli R; Beuthien-Baumann B; Kurz A; Minoshima S; de Leon MJ
    J Nucl Med; 2008 Mar; 49(3):390-8. PubMed ID: 18287270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria.
    Caminiti SP; Sala A; Iaccarino L; Beretta L; Pilotto A; Gianolli L; Iannaccone S; Magnani G; Padovani A; Ferini-Strambi L; Perani D
    Alzheimers Res Ther; 2019 Feb; 11(1):20. PubMed ID: 30797240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.
    Roy K; Pepin LC; Philiossaint M; Lorius N; Becker JA; Locascio JJ; Rentz DM; Sperling RA; Johnson KA; Marshall GA
    J Alzheimers Dis; 2014; 42(1):291-300. PubMed ID: 24898635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
    Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L;
    Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of 18F-FDG-PET/MRI brain in dementia: Preliminary experience from a geriatric clinic in South India.
    Mukku SSR; Sivakumar PT; Nagaraj C; Mangalore S; Harbishettar V; Varghese M
    Asian J Psychiatr; 2019 Aug; 44():99-105. PubMed ID: 31336358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients.
    Jeong Y; Cho SS; Park JM; Kang SJ; Lee JS; Kang E; Na DL; Kim SE
    J Nucl Med; 2005 Feb; 46(2):233-9. PubMed ID: 15695781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.